Select year

2026 2025 2024 2023 2022 Earlier

shown/page

10

2026.07.17

ThalassaX Therapeutics Announces First Patient Dosed in U.S. Phase I Trial of CS231295, a Brain-Penetrant Aurora B Kinase Selective Inhibitor
ThalassaX Therapeutics Announces First Patient Dosed in U.S. Phase I Trial of CS231295, a Brain-Penetrant Aurora B Kinase Selective Inhibitor

2026.07.15

Chipscreen Biosciences' Partner HUYABIO Announces Positive Topline Data from Global Multicenter Phase III Trial of Chidamide (Epidaza®) in Melanoma
Chipscreen Biosciences' Partner HUYABIO Announces Positive Topline Data from Global Multicenter Phase III Trial of Chidamide (Epidaza®) in Melanoma

2026.06.12

Chipscreen Biosciences Attends the 2026 SAPA Healthcare Investment Forum, Engaging with the Global Innovation Ecosystem
Chipscreen Biosciences Attends the 2026 SAPA Healthcare Investment Forum, Engaging with the Global Innovation Ecosystem

2026.05.25

From Glycemic Control to Addressing Metabolic Root Causes: “White Paper on the Current Status and Future of Comprehensive Insulin Resistance Management in China (2025)” Officially Released
From Glycemic Control to Addressing Metabolic Root Causes: “White Paper on the Current Status and Future of Comprehensive Insulin Resistance Management in China (2025)” Officially Released

2026.05.14

Two First-in-Class Drugs from Chipscreen Biosciences Enter the Macao Market, Expanding Patient Access
Two First-in-Class Drugs from Chipscreen Biosciences Enter the Macao Market, Expanding Patient Access

2026.04.23

2026 ASCO丨Multiple innovative Drug Studies from Chipscreen Biosciences Selected
2026 ASCO丨Multiple innovative Drug Studies from Chipscreen Biosciences Selected

2026.04.23

Published in JAMA ! Chidamide DEB Study Reshapes the First-Line Treatment Landscape for DE-DLBCL
Published in JAMA ! Chidamide DEB Study Reshapes the First-Line Treatment Landscape for DE-DLBCL

2026.04.18

AACR 2026 | Dual Breakthroughs in Novel Target ADCs and Small Molecules: Four Original Oncology Pipeline Studies from Chipscreen and Chipscreen Newway Biosciences Accepted for Presentation
AACR 2026 | Dual Breakthroughs in Novel Target ADCs and Small Molecules: Four Original Oncology Pipeline Studies from Chipscreen and Chipscreen Newway Biosciences Accepted for Presentation

2026.03.16

First-in-Class Combination Therapy: Clinical Trial Application for Chiglitazar Sodium/Metformin Extended-Release Tablets for Type 2 Diabetes Approved
First-in-Class Combination Therapy: Clinical Trial Application for Chiglitazar Sodium/Metformin Extended-Release Tablets for Type 2 Diabetes Approved

2026.03.16

Chipscreen Biosciences Receives NMPA Approval for IND of Novel PRMT5 Inhibitor CS08399 for MTAP-Deficient Tumors
Chipscreen Biosciences Receives NMPA Approval for IND of Novel PRMT5 Inhibitor CS08399 for MTAP-Deficient Tumors

Media contact

Media contact

（+86）0755-36993500
pr@chipscreen.com